Ameriprise Financial Inc. Has $635,000 Holdings in ClearPoint Neuro, Inc. (NASDAQ:CLPT)

Ameriprise Financial Inc. grew its position in ClearPoint Neuro, Inc. (NASDAQ:CLPT) by 7.1% during the 4th quarter, Holdings Channel.com reports. The firm owned 41,316 shares of the company’s stock after purchasing an additional 2,742 shares during the period. Ameriprise Financial Inc.’s holdings in ClearPoint Neuro were worth $635,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. R Squared Ltd acquired a new stake in ClearPoint Neuro during the 4th quarter worth approximately $32,000. AlphaQuest LLC bought a new position in ClearPoint Neuro during the 4th quarter worth $80,000. Tower Research Capital LLC TRC acquired a new stake in shares of ClearPoint Neuro during the fourth quarter worth $93,000. ExodusPoint Capital Management LP bought a new stake in shares of ClearPoint Neuro in the fourth quarter valued at about $204,000. Finally, MGO One Seven LLC bought a new stake in shares of ClearPoint Neuro in the fourth quarter valued at about $269,000. Institutional investors and hedge funds own 30.08% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on CLPT shares. Wall Street Zen lowered shares of ClearPoint Neuro from a “hold” rating to a “sell” rating in a research report on Thursday, May 22nd. Stifel Nicolaus lifted their price target on shares of ClearPoint Neuro from $19.00 to $25.00 and gave the company a “buy” rating in a research report on Tuesday, April 1st.

ClearPoint Neuro Stock Performance

Shares of NASDAQ CLPT opened at $12.66 on Wednesday. The stock has a market capitalization of $354.34 million, a P/E ratio of -18.35 and a beta of 1.03. The stock’s fifty day moving average is $12.65 and its 200 day moving average is $14.24. ClearPoint Neuro, Inc. has a 52 week low of $5.11 and a 52 week high of $19.22.

ClearPoint Neuro (NASDAQ:CLPT) last released its earnings results on Tuesday, May 13th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.07). The firm had revenue of $8.49 million during the quarter, compared to the consensus estimate of $8.21 million. ClearPoint Neuro had a negative net margin of 59.64% and a negative return on equity of 62.10%. Equities research analysts forecast that ClearPoint Neuro, Inc. will post -0.66 earnings per share for the current year.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.